INSTITUT FUR MOLEKULARE UND KLINISCHE OPHTHALMOLOGIE BASEL

Their core work

The Institute of Molecular and Clinical Ophthalmology Basel (IOB) is a Swiss research center focused on understanding the human retina — how it develops, how it functions at the single-cell level, and how it fails in degenerative diseases. Their work spans from fundamental neuroscience of visual circuits to applied approaches like retinal organoids and artificial retina technologies. They combine advanced imaging techniques (two-photon imaging), optogenetics, and single-cell genomics to map and manipulate retinal neurons, positioning them at the intersection of basic vision science and therapeutic development.

What they specialise in

How they've shifted over time

Their early H2020 work (2015–2019) focused on fundamental visual neuroscience — understanding how the retina communicates with the brain (RETMUS) and participating in comparative organoid biology for evolutionary studies (ANTHROPOID). From 2020 onward, the focus sharpened dramatically toward applied retinal medicine: mapping the human retina at single-cell resolution (HURET) and exploring bio-hybrid artificial retina devices (HyVIS). The trajectory shows a clear shift from basic circuit neuroscience toward translational ophthalmology and vision restoration technologies.

IOB is moving toward therapeutic applications — anyone working on vision restoration, retinal prosthetics, or organoid-based disease modeling should consider them a future partner.

How they like to work

IOB operates as both a project leader and a specialist contributor, splitting evenly between coordinating (RETMUS, HURET) and participating (ANTHROPOID, HyVIS). Their consortia are small and focused — only 7 unique partners across 5 countries — suggesting they prefer tight, expert-driven collaborations over large multi-partner networks. This makes them a reliable, deeply engaged partner rather than a passive name on a consortium list.

IOB has worked with 7 distinct partners across 5 European countries, forming compact research teams. Their network is modest in size but strategically concentrated in vision science and advanced biomaterials.

What sets them apart

IOB occupies a rare niche: a dedicated ophthalmology research institute that bridges molecular-level retinal biology with emerging bio-hybrid technologies like artificial retinas. Unlike university eye clinics focused on patient care or engineering labs focused purely on devices, IOB connects deep biological understanding of how retinal circuits work with materials science approaches (plasmonics, metamaterials) for vision restoration. Their ERC-funded single-cell mapping of the human retina (HURET, €2.5M) gives them a foundational dataset that few organizations worldwide can match.

Highlights from their portfolio

• HURET
  Largest project (€2.5M ERC Advanced Grant) — an ambitious effort to map the entire human retina at single-cell resolution, combining optogenetics, organoids, and two-photon imaging.
• HyVIS
  Represents their translational frontier — a bio-hybrid artificial retina project merging neuroscience with plasmonics and smart polymers, signaling a move toward therapeutic devices.
• ANTHROPOID
  Demonstrates cross-disciplinary range — IOB contributed organoid expertise to a project studying great ape brain development and human evolutionary biology.